Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report - Scorecard - MDSpire

Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report

  • By

  • Luca Carlofrancesco Ammoni

  • Giorgia Carola

  • Giuseppe Ippolito

  • Alice Baggi

  • Francesca Consoli

  • Andrea Esposito

  • Ilaria Pedrazzini

  • Alfredo Berruti

  • Salvatore Grisanti

  • May 28, 2026

  • 0 min

Share

Clinical Scorecard: Addressing Severe Dysphagia in a 30-Year-Old Female with Advanced ALK-Positive Non-Small Cell Lung Cancer: A Case Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationYoung, never-smoker patients with advanced ALK-positive NSCLC.
Care Setting

Key Highlights

  • Lorlatinib is a third-generation ALK TKI effective in first-line therapy, as demonstrated in the CROWN study.
  • Severe dysphagia was managed by administering lorlatinib via a nasogastric tube.
  • Rapid reduction of cervical lymph node swelling was observed within days.
  • Imaging showed partial response at two weeks and complete metabolic response at six months.
  • Lorlatinib was well tolerated with only increased cholesterol levels reported.

Guideline-Based Recommendations

Diagnosis

    Management

    • First-line treatment with lorlatinib 100 mg daily, as per the CROWN study.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        30-year-old female with advanced ALK-positive NSCLC.

        Lorlatinib can be administered crushed via nasogastric tube for patients with dysphagia.

        Clinical Best Practices

        • Consider alternative administration routes for patients unable to swallow.

        Related Resources & Content

        Original Source(s)

        Overcoming absolute dysphagia in a thirty-year-old patient with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report

        • by Luca Carlofrancesco Ammoni, Giorgia Carola, Giuseppe Ippolito, Alice Baggi, Francesca Consoli, Andrea Esposito, Ilaria Pedrazzini, Alfredo Berruti, Salvatore Grisanti

        • May 28, 2026

        Related Content

        Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

        Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

        Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”